

Press Release

August 8, 2007

Bernd Ebeling
Director Corporate Communications
Corporate Communications
and Public Affairs

Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2378
F +49 6172 608-2294
bernd.ebeling@fresenius.com
www.fresenius.com

Health Care Group Fresenius with new Corporate Design

Having successfully completed its conversion into a European Company (SE) in July, Fresenius has now also given itself a new look.

The Group's corporate logo, colors and fonts have been revised and updated. The "F" in the new logo builds on the previous logo. Its form represents the Company's aspirations and continued growth. While the logo remained unchanged for over 13 years, Fresenius has grown significantly. Sales rose more than 10-fold from about € 1 billion in 1994 to € 10.8 billion in 2006, and the number of employees climbed from 8,000 in 1994 to about 109,000 this year.

Fresenius will continue to use its traditional blue color to represent the company, though in darker shade. The new corporate font "Interstate" is notable for its clarity. The business segments Fresenius Medical Care, Fresenius Kabi, Fresenius HELIOS and Fresenius VAMED will also review their corporate design.

To take a closer look at Fresenius SE's new corporate design, go to our German website at www.fresenius.de or our English website at the new address www.fresenius.com.

You will find the new Fresenius company logo in print quality at www.fresenius.de/logos.

#

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2006 group sales were approx. € 10.8 billion. On June 30, 2007 the Fresenius Group had 108,860 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Board of Management: Dr. Ulf M. Schneider (President and CEO), Rainer Baule, Andreas Gaddum, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm
Supervisory Board: Dr. Gerd Krick (Chairman)
Registered Office: Bad Homburg, Germany/Commercial Register No. HRB 10660